A decade-long legal fight against the company that did more than any other to seed the modern opioid crisis is now translating into real dollars on the ground in New Hampshire. As NHPR reports in a story originally produced by the Concord Monitor, Attorney General John Formella confirmed that the state will receive more than $29.5 million from Purdue Pharma and members of the Sackler family as a $7.4 billion nationwide settlement takes effect.
About $16.2 million of that is expected to land in the next three years. The rest will be paid out across a longer schedule under a national framework joined by attorneys general from every state and eligible U.S. territory.
What The Settlement Actually Settles
The Sackler family — the longtime owners of Purdue Pharma — is, as a condition of the deal, permanently barred from selling opioids in the United States. That ban, more than the dollar figure, is what state attorneys general have spent the better part of a decade chasing. The Sacklers have been widely identified, in court filings and reporting on both sides of the country, as principal architects of the marketing campaign that pushed OxyContin into the mainstream of American pain management in the late 1990s and early 2000s.
For New Hampshire, the toll of that campaign has been brutally specific. Opioid-related deaths in the Granite State peaked in 2017 at 416 — a per-capita rate of roughly 33.4 per 100,000 residents — and resurged during the pandemic before easing again. In 2024, state data recorded 248 overdoses involving opioids. That is fewer, but still hundreds of people, and the underlying treatment infrastructure remains thin.
“For too long, they profited while communities like ours paid the price. While no amount of money can undo the harm caused to families across New Hampshire, this agreement delivers both accountability and meaningful resources,” Formella said in announcing the disbursement. “We remain committed to working with our local partners to ensure these funds are used where they are needed most to save lives and support long-term recovery.”
Gov. Kelly Ayotte echoed the framing. “The opioid crisis has devastated families in our state, and I thank the Attorney General’s Office in New Hampshire and AGs across the country who have worked tirelessly to hold Purdue Pharma accountable for their role in poisoning our communities,” she said in a statement.
How The Money Will Be Split In New Hampshire
State law dictates how the settlement is allocated once it crosses into Granite State accounts. Fifteen percent — just under $4.5 million — will be divided among cities and counties on a per-capita basis. Concord, Manchester, Nashua, and the larger counties will see the bulk of that pool, but every municipality is entitled to a share.
The remaining 85 percent goes into the state’s Opioid Abatement Trust Fund. That fund is overseen by an advisory commission tasked with deciding which specific organizations and programs receive grants. In practice, that means the lion’s share of New Hampshire’s settlement is intended for prevention work, treatment programs, and recovery services — not general state revenue.
That is a meaningful design choice. In some states, opioid settlement money has been quietly absorbed into general budget lines, replacing existing appropriations rather than expanding services. New Hampshire’s structure, with a dedicated trust and an advisory commission, makes that kind of slippage harder, though not impossible.
The Treatment Infrastructure The Money Has To Plug Into
There is a second question hanging over the disbursement: whether the state’s existing treatment infrastructure has the capacity to absorb a meaningful expansion. New Hampshire has spent the better part of a decade trying to stand up a coordinated continuum of care — outpatient clinics, residential treatment, medication-assisted treatment programs, peer recovery networks, and post-release services for people leaving the corrections system. The system is still uneven, particularly outside of Manchester, Nashua, and the Seacoast.
That uneven geography is part of why opioid settlement dollars flowing into community-level providers matter so much. The same rural healthcare workforce gap that has driven interest in the Go North initiative to attract billions in rural healthcare investment also constrains what an addiction treatment dollar can actually buy in the North Country. The settlement money does not, by itself, hire new clinicians or open new beds. It funds programs that have to find clinicians and beds in a tight labor market.
The role of public coverage in keeping that infrastructure standing has been a recurring theme in coverage of how Medicaid functions as the foundation of New Hampshire’s healthcare system. Most addiction treatment in the state is paid for, directly or indirectly, through Medicaid. Settlement dollars layer on top of that floor; they do not replace it.
What Comes Next
The advisory commission overseeing the Opioid Abatement Trust Fund will continue to issue grant cycles to qualifying programs. Local governments will begin receiving their per-capita shares as the settlement payments are released on schedule. And the practical question — whether the next decade of opioid policy in New Hampshire produces fewer overdoses than the last decade did — will be answered not in courtrooms or press conferences but in clinics, sober houses, jails, and emergency rooms across the state.
For families who lost someone in the worst years of the crisis, the agreement does not bring a person back. What it does is force the people who profited from the sale of OxyContin to put a dollar figure on what they did, and to put that money toward repair.
